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Abstract
Background: Type 2 diabetes and periodontitis predispose to a higher risk of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Recent
studies show upregulation of innate immuno-regulatory microRNA-146a and -
155 in oral fluids of patients with type 2 diabetes as well as of patients with peri-
odontitis. The aim was to investigate whether upregulation of these microRNAs
may relate to patient susceptibility to the infection via modulation of SARS-CoV-
2 cellular entry factors expression.
Methods: Due to limited experimental feasibility and health risks in Coron-
avirus Disease 2019, bioinformatic analyses combining with system biology were
used as initial investigation of interaction between microRNA-146 and -155 and
genes encoding SARS-CoV-2 entry factors.
Results: SARS-CoV-2 cellular entry factors are expressed in salivary glands and
masticatory mucosa (tongue) at different expression levels, comparable with
those measured in lungs and tonsil. MicroRNA-146 and -155 are widely involved
in the regulation of SARS-CoV-2 oral cellular entry factors and may enhance
expression of ACE2 and modulate genes involved in host immunity.
Conclusions: Diabetes- and periodontitis-induced increase in microRNA-146a
and -155 in oral cavity is predicted to upregulate angiotensin-converting enzyme
2 expression, essential SARS-CoV-2 entry receptors, and modulate host antiviral
response. As it could suggest increased infectivity of diabetes and periodontitis
patients, additional protective measures for periodontists are recommended.
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1 INTRODUCTION
The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection causes systemic inflammatory
response due to release of large amounts of proinflam-
matory cytokines by immune cells during the infection.1
Nevertheless, the mechanism of virus invasion and the
causes of these aberrant inflammatory responses in SARS-
CoV-2 infection remain largely unknown. Moreover, evi-
dence demonstrates that peoplewith underlyingmetabolic
conditions such as type 2 diabetes mellitus, are at higher
risk of severe Coronavirus Disease 2019 (COVID-19), asso-
ciated with more efficient virus entry.2 A very recent
study by Katz et al.3 showed that dental diseases are
associated with increased odds ratio for COVID-19 and
that patients with periodontal disease were 4.7 times
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more likely to have COVID-19, after adjustment for
smoking.3 Based on significant association of periodon-
titis with diabetes as well as known systemic inflam-
matory reaction, periodontitis was proposed to be a risk
factor for SARS-CoV-2 infection.4 Infection by human
coronaviruses as well as other respiratory viruses highly
depends on host microRNA (miR) involvement which
maintains the epithelial cell barrier in the respiratory
tract and modulates virus entry and replication.5 miR-
146a and miR-155 are the first miRs induced during
immune activation and modulate the Toll-like receptor
(TLR)-signaling pathways which trigger the production
of large amounts of inflammatory cytokines, type I inter-
ferons (IFNs), and antiviral proteins via nuclear factor-
kappa B (NFκB).6 Regarding SARS-CoV-2, very recent
in-silico analyses showed that among 28 human miRs
predicted to target at the SARS-CoV-2 genome, miR-146
and the immune response as the function were seriously
affected by the virus infection. Furthermore, the authors
of the study proposed that miR-146 could be “hijacked”
by the virus genome to modulate host biological pro-
cesses by affecting genes that originally are targeted by this
miR.7
Recent studies show that states of type 2 diabetes and
chronic periodontitis show upregulation of miR- 146a
and -155 in oral fluids: patients with type 2 diabetes
express higher expression of crevicular fluid miR-146a8
and salivary miR-146a and miR-1559 while patients with
periodontitis express higher expression of miR-146a and
miR-155 in crevicular fluid8 and saliva.9,10 ThesemiRs, per-
sisting in body fluids as circulatory and exosomal, could
be taken up by diverse oral cavity-neighbor or distant cells
such as epithelial cells, endothelial or immune cells acting
in local as well as systemic intercellular communication
and immune regulatory function.11 The aim was to inves-
tigate whether upregulation of these immunomodulating
and oral cavity-circulatingmiRs in periodontitis and type 2
diabetes could be related to susceptibility of these patients
to SARS-CoV-2 infection, by computational analysis of
interaction between miR-146 and -155 and genes encoding
SARS-CoV-2 oral cellular entry factors.
2 MATERIALS ANDMETHODS
Due to the limitation of experimental feasibility and
health risks during COVID-19, the usage of in-silico target
identification algorithms, as an initial strategy with the
advantage of fast speed and low cost, could be important
for the emerging information aiming to improve dental
practice and reduce health risks. In-silico characterization
presently was performed by using approaches such as
expression profiling of human genes related to SARS-CoV-
2 entry, gene/protein-network mapping, protein- protein
interactions, and gene expression predictions.
2.1 Expression profiling of SARS-CoV-2
cellular entry factors in oral cavity
The lst of cellular factors regulating SARS-CoV-2 entry into
cells is derived from experimental studies of SARS-CoV-2
but also of severe acute respiratory syndrome coronavirus
(SARS-CoV) and Middle East respiratory syndrome coro-
navirus (MERS-CoV). Angiotensin-converting enzyme 2
(ACE2) has been considered the major receptor for SARS-
CoV-2 entry into target cells while the transmembrane ser-
ine protease 2 (TMPRSS2) cleaves ACE2 and facilitates the
entry of SARS-CoV into host cells.13 Cell surface protein
basigin (BSG, also known as CD147) has been proposed
as alternative receptor for SARS-CoV-214,15 while cathep-
sins (CTSL/B) andFURINcan also substitute for TMPRSS2
to prime SARS-CoV.16 Receptors which have been con-
firmed experimentally to facilitate entry of either SARS-
CoV (ANPEP, CD209, CLEC4G/M) or MERS-CoV (DPP4)
were included in the investigation as candidates for pro-
moting SARS-CoV-2 entry.12 To identify the tissue localiza-
tion of potential SARS-CoV-2 cellular receptors, the pub-
licly available, The Human Protein Atlas online program
was used.17 The Tissue Atlas contains information regard-
ing the expression profiles of human genes both on the
mRNA and protein level. The mRNA expression data are
derived from deep sequencing of RNA (RNA-seq) from 37
different normal tissue types. Consensus transcript expres-
sion levels for each gene were summarized based on tran-
scriptomics data from three sources:HPA,GTEx, andFAN-
TOM5. The consensus normalized expression (NX) value
for each gene and organ/tissue represents the maximum
NX value in the three data sources.
2.2 Interaction networks
ACE2-associated genes used for constructing interaction
networks andmiR prediction analyseswere extracted from
StringApp 1.5.1 (Search Tool for the Retrieval of Interacting
Genes/Proteins) database (https://string-db.org) (top 10
ACE2 interactors), Archs4 database (https://amp.pharm.
mssm.edu/archs4) (top 10 genes with correlated expres-
sion) and Genecards database (https://www.genecards.
org) (five interactors). For TMPRSS-2 -interaction network
and miR predictions data are based on StringApp 1.5.1 (top
10 TMPRSS2 interactors), Archs4 database (top five genes
with correlated expression), and Genecards database (five
interactors). To analyze connections between ACE2 and
TMPRSS2 genes and their interactors, a protein-protein
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ACE2 1.1 0.5 0.8 0.2 122.0
TMPRSS2 52.3 3.9 20.7 10.2 75.6
FURIN 337.9 5.5 9.5 4.1 5.9
BSG 44.0 45.9 36.1 31.2 45.5
CD209 3.0 2.1 3.7 1.3 10.1
DPP4 46.9 1.4 5.4 1.1 133.1
CLEC4G/M 4.9 0.6 0.5 0.2 0.7
ANPEP 6.6 4.2 9.7 3.8 155.8
CTSL 22.0 9.4 53.1 10.1 12.0
CTSB 63.7 25.9 94.3 38.4 51.2
ACE2, angiotensin-converting enzyme 2; ANPEP, alanyl aminopeptidase; BSG, basigin; CD209, cluster of differentiation 209; CLEC4G/M, C-type lectin domain
family 4 member G/M; CTSB, cathepsin B; CTSL, cathepsin L; DPP4, dipeptidyl peptidase-4; TMPRSS2, transmembrane serine protease 2.
*Based on the mRNA data obtained from The Human Protein Atlas.
interaction (PPI) network in Cytoscape 3.8.0 were con-
structed, using human interactome data from StringApp
1.5.1 database, including known and predicted pro-
tein‒protein interactions. Interaction networks were com-
posed from a set of genes/proteins (nodes) connected
by edges which represent functional relationships among
these genes/proteins. Connections with edge interaction
confidence cut-off > 0.4, (with 1.0 being the highest pos-
sible confidence) were considered.
2.3 MicroRNA predictions
To predict miR-146 and miR-155- regulation of SARS-CoV-
2 oral cellular entry factors, TargetScan 7.2 is used. Tar-
getScanHuman predicts biological targets of microRNAs
by analyzing different miRNA-mRNA seed-site interac-
tion patterns.18 Predictions are presented as predicted effi-
cacy of targeting, calculated using cumulative weighted
context++ scores of the sites representing the sum of
the contribution of 14 interaction-relevant features.19 This
score estimates the total repression expected frommultiple
sites of the same miRNA, for each mRNA target predicted
and the more negative the score, the repression is greater.
3 RESULTS
3.1 Tissue-specific expressions of
SARS-CoV-2 entry factors
Analysis based on the mRNA data obtained from The
Human Protein Atlas revealed that SARS-CoV-2 cellular
entry factors are expressed in salivary glands and masti-
catory mucosa (tongue) at different expression levels. The
highest gene expression in masticatory mucosa expresses
BSG while CLEC4G/M and ACE2 genes show the lowest
expression levels. In salivary glands (samples from minor
and major glands), FURIN is expressed at the highest, and
ACE2 at the lowest levels. However, even at low expression
levels, ACE2 expression levels in the oral cavity were com-
parable with thosemeasured in lungs and tonsil. The high-
est expression levels for ACE2 and TMPRSS2 were shown
in small intestine (Table 1).
3.2 Prediction of miR-146 and miR-155
targeting SARS-CoV-2 oral cellular entry
factors
Firstly, ACE2 and TMPRSS2 interaction networks were
analyzed at the first level interactors including virus-
related proteins from ACE2 (ACE2, DPP4, ANPEP,
CLEC4M) and TMPRSS2 (TMPRSS2, CTSB, CTSL,
FURIN) interaction networks. Present in-silico analyses
show that miR-146 and -155 are widely involved in the neg-
ative regulation of genes encoding SARS-CoV-2 cellular
entry factors and their interactors present in the oral cavity
(Fig. 1, Table 2). In ACE2 interaction network, miR-146
andmiR-155 negatively regulate ACE2-co-expressed genes,
AGTR1 and membrane metallo-endopeptidase (MME),
as well as prolyl carboxypeptidase (PRCP) gene with
highest predicted efficacy of miR-155 targeting AGTR1.
In TMPRSS2 interaction network, the highest predictive
efficacy miR-146 and miR-155 show in targeting transcrip-
tion factor NKX3-1 (Fig. 1, Table 2). Importantly, miR-146
is predicted to directly suppress FURIN, BSG, and CTSB
genes expression, showing the highest predictive efficacy
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F IGURE 1 Predicted miR-146 and -155 targeting in ACE2 (a) and TMPRSS2 (b) interaction networks. Nodes represent the first level
ACE2 and TMPRSS2 interactors connected by edges which represent functional relationships among these genes/proteins. For clarity, only the
edges connecting ACE2 and TMPRSS2 with interactors negatively regulated by miR-146 and/or miR-155 were presented. ACE2, angiotensin-
converting enzyme 2; AGTR1, angiotensin II receptor type 1; AR, androgen receptor; CAT, catalase; CLEC4M, C-type lectin domain family 4
memberM; CTSB, cathepsin B; ERG, ETS transcription factor; ETV1, ETS variant transcription factor 1; FABP2, fatty acid binding protein 2 (the
second levelACE2 interactor);MME,membranemetallo-endopeptidase, neprilysin;NKX3-1, homeobox protein; PRCP, prolylcarboxypeptidase;
PTEN, phosphatase and tensin homolog; TMPRSS2, transmembrane serine protease 2. Gene neighborhood (green line); gene co-occurrence
(blue line); co-expression (black line); text mining (yellow line)
of targeting BSG (Fig. 2) while miR-146 and -155 could
indirectly regulate other alternative SARS-CoV-2 entry
regulators: CD209 (by suppressing regulating genes KRAS
and NRAS), ANPEP (by suppressing CD33), CLEC4G/M
(by suppressing BACE1, CLEC5A, and TYRO3), and DPP4
(by suppressing MME and PRCP) (Fig. 2)
3.3 Prediction of miR-146 and miR-155
targeting viral entry-related, host
immune-regulating genes
Host immune-regulating genes being first level interac-
tors within SARS-CoV-2 entry receptor (ACE2, ANPEP,
CD209) networks and the predicted effects of their interac-
tion with miR-146 and miR-155 were presented in Table 3.
The highest predicted efficacy in repression shows miR-
155 targeting CD33 gene (cumulative weighted context++
scores: −0.43) followed by miR-146 targeting NRAS gene
(cumulative weighted context++ scores: −0.36) and miR-
146 targeting CLEC5A (cumulative weighted context++
scores: −0.22) (Table 3).
Immunomodulatory effects on host antiviral responses
by miR-146 and miR-155, mediated by TLRs- downstream
effectors and shown in in vitro and in vivo studies with
other respiratory viruses, are presented in Table 4.
F IGURE 2 Predicted efficacy of miR-146 and -155 targeting
alternative SARS-CoV-2 oral cellular entry factors. Bars represent
absolute values of cumulative weighted context++ scores estimat-
ing the total repression expected from multiple sites of the same
miRNA, for each mRNA target predicted. ANTXR1, anthrax toxin
receptor 1; BACE1, beta-secretase 1; BSG, basigin; CD33, siglec-
3; CLEC5A, C-type lectin domain family 5 member A; CTSB,
cathepsin B; HLA, DRB1 – HLA class II histocompatibility anti-
gen, DR-1 beta chain; HSPG2, heparan sulfate proteoglycan 2;
KRAS, Kirsten rat sarcoma viral proto-oncogene; MME, membrane
metallo-endopeptidase, neprilysin; NRAS, neuroblastoma RAS viral
oncogene homolog; PPIL2, peptidyl-prolyl cis-trans isomerase-like
2; PRCP, prolylcarboxypeptidase; TYRO3, tyrosine-protein kinase
receptor TYRO3
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AGTR1 ACE2 miR-155 −0.27
MME ACE2 miR-146 −0.12
PRCP ACE2 miR-146 −0.02
CLEC4M ACE2 miR-146 −0.22
CAT ACE2 miR-146 −0.12









ETV1 TMPRSS2 miR-155 −0.09





FURIN TMPRSS2 miR-146 −0.02
CTSB TMPRSS2 miR-146 −0.01
ACE2, angiotensin-converting enzyme 2; TMPRSS2, transmembrane serine protease 2; AGTR1, angiotensin II receptor type 1; MME, membrane metallo-
endopeptidase, neprilysin; PRCP, prolylcarboxypeptidase; AR, androgen receptor; ERG, ETS transcription factor; ETV1, ETS variant transcription factor1; PTEN,
phosphatase and tensin homolog; NKX3-1, homeobox protein. The more negative the score, the greater the repression.
aTargetScan 7.2.




Predicted miR -146a and -155 modulated
host immune responses
CLEC5A ACE2 miR-146 By suppression of CLEC5A/TLR2 signaling-
inhibition of production of cytokines
(TNF-α, IL-1, IL-6, IL-8, IL-17) and
chemokines. Overactivation of
CLEC5A/TLR2 is detrimental during acute
viral infections.
KRAS CD209 miR-146miR-155 Inhibition of Ras/NFkB signaling: reduction in
production of proinflammatory cytokines:
IL-17, IL-22, IFN-γ, TNF-α, IL-6.
NRAS CD209 miR-146 Reduction in production of proinflammatory
cytokines: IL-17, IL-22, IFN-γ, TNF-α, IL-6.
CD33 ANPEP miR-155 Upregulation of proinflammatory cytokines:
IL-1β, IL-8, TNF-α
CAT ACE2 miR-146 Oxidative stress
4 DISCUSSION
Comprehensive overview on cellular factors that could
be involved in SARS-CoV-2 entry show that they are
expressed in masticatory mucosa as well as in salivary
glands located throughout the oral cavity inmRNA expres-
sion levels comparable with lungs or tonsil suggest-
ing SARS-CoV-2 tropism for oral tissues. Recent RNA
sequencing transcriptome profiling of samples of oral
mucosa show that 2% of non-immune mouth tissue cells
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TABLE 4 miR-146a and miR-155- immunomodulatory effects in host defense responses to respiratory viruses
Respiratory virus
(cells/samples used) miR Effects Pathways and targets
Rhinovirus (human bronchial
epithelium-in vitro)40
miR-155 Inhibition of viral
replication
Promoting IFN signaling






















Inhibiting IFN production by
targeting TRAF6,
TLRs-downstream effector
Influenza viruses: H1N1 and
H3N3 (human pulmonary
epithelium in vitro)42
miR-146a Decrease in viral
production
miR-146a-induced cellular
antiviral activity or direct
inhibition of viral genes?
H3N2 (human nasal
epithelium in vitro)43




compared with 2.5% of non-immune nasal tissue cells
and 5.6% of non-immune lung tissue cells, express ACE2
expression and that ACE2 is frequently co-expressed with
TMPRSS2 in oral tissues.20 Furthermore, ACE2 receptor
mRNA expression level was relatively high in epithelial
cells, higher in oral tongue than buccal and gingival tis-
sues, and less pronounced in fibroblasts.21 Expression of
ACE2 protein detected by polyclonal antibody revealed
moderate to strong staining covering >75% of the epithe-
lium of oral mucosa and salivary glands, and weak stain-
ing in fibroblasts and immune inflammatory cells of oral
cavity.22
Present in-silico analyses showed that miR-146 and
miR-155 are widely involved in the regulation of cellular
factors present in oral mucosa and important for SARS-
CoV-2 entry. Regulation of essential viral receptor, ACE2,
by miRs seems to be indirect, by suppressing co-expressed
genes: miR-155 express high efficacy in targeting and
suppressing AGTR1 expression while miR-146 suppresses
gene expression of membrane metallo-endopeptidase
(MME, neprilysin) and prolyl carboxypeptidase (PRCP).
As the first level ACE2 interactors, they represent
components of renin-angiotensin system, involved in
metabolism of bioactive peptides known to regulate vascu-
lar homeostasis.23 Since negative regulation of AGTR1 and
lack of PRCP increase ACE2 expression,24–26 these results
imply miR-146 and -155 could promote ACE2 gene expres-
sion. In-silico analyses are associated with limitations:
the accuracy of the predictions is mainly limited by the
amount of data used in the underlying algorithms, thus
experimental data are needed. The predicted upregulation
of ACE2 expression in periodontitis and diabetes needs to
be validated in the clinical studies. Recent data investigat-
ing ACE2 expression in lung tissue of patients with type
2 diabetes showed that protein levels of ACE2 were sig-
nificantly increased in both alveolar tissue and bronchial
epithelium of patients with diabetes.27 Opposite to our
predictions, a single study, on a limited number of human
gingival samples, showed weaker ACE2 immunostaining
in periodontitis comparedwith healthy gingival samples.28
Caution must be taken regarding the interpretation of
this result since Descamps et al.22 suggested that lack of
ACE2 immunostaining in oral tissues could be explained
by the cleavage of ACE2 receptor by disintegrin and
metalloproteinase (ADAM 17), activity of which enhances
in inflammatory states,29 such as periodontitis.
Noteworthy, miR-155 and especially miR-146, nega-
tively regulate other potential cellular entry factors. Data
suggest TMPRSS2 gene regulation is via androgens and
present results show that miR-146 and -155 are suppres-
sors of androgen signaling showing the highest efficacy
in suppressing transcription factor homeobox protein
(NKX3-1) which negatively regulates androgen receptor
(AR) transcriptional activity30 and indirectly TMPRSS2.
miR-146 directly negatively regulates CTSB gene expres-
sion and with high predicted efficacy represses expression
of alternative viral receptor and activating factor: BSG and
FURIN.
Nevertheless, ACE2 seems to be essential and sufficient
for SARS-CoV-2 cellular entry since soluble extracellu-
lar domain of ACE2 as well as antibodies targeting the
receptor binding element can effectively block infection.31
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The expression pattern of ACE2 in oral tissues in patients
with type 2 diabetes and periodontitis need validation
in the clinical studies, but based on the epidemiological
data, patients with periodontal disease and diabetes are at
higher risk for SARS-CoV-2 infection, thus additional pro-
tective measures are needed for periodontists.
Besides regulating the SARS-CoV-2 entry receptors
genes, overexpressed miR-146 and miR-155 could con-
tribute to viral propagation by affecting antiviral host
defense. Presently reported repressive effects of miR-146
and -155 on genes included in SARS-CoV-2 entry revealed
also signaling pathways of miR-146 and -155 immunomod-
ulatory effects: bymiR-146- suppression ofCLEC5A, highly
expressed on myeloid lineages, inhibition of production of
cytokines and chemokines, and attenuated innate immune
response32 could be proposed. By suppression of KRAS
and NRAS-inhibition of RAS signaling pathway, sup-
pression of NFkB-cytokine production33 by both miR-
146 and miR-155 is proposed while by suppression of
CD33, transmembrane receptor in myeloid cells, induc-
tion of proinflammatory cytokines34 by miR-155 may be
proposed. These results imply miR-146a-suppressive and
miR-155-stimulating effects on production of cytokines
which combat invading pathogens. Thus, the miR-146a
and miR-155 interplay may help maintain the inflamma-
tory response but minimize tissue damage while inducing
an effective immune response for viral clearance. Another
immunomodulatory effect by miR-146a and miR-155 on
host antiviral responses via TLRs-downstream effectors,
shown in studies with other respiratory viruses should
be considered also. It could be assumed that these miR-
146a and -155-regulated inflammatory pathways affect host
defense mechanisms against SARS-CoV-2 but may be
engaged in the host anti-inflammatory responses to type
2 diabetes and chronic periodontitis also.
Furthermore, it has been pointed out that altered
immune response by overexpressedmiR-146a can be trans-
ferred via exosomes to the neighbor or distant cells mak-
ing them more susceptible for virus infection.35 Neverthe-
less, while miR-155 may stimulate host antiviral defense,
immunosuppressive actions of miR-146a could have ben-
eficial effects for the host by counteracting the danger-
ous excessive inflammatory reaction. Indeed, upregulation
of miR-146a contributes to suppression of inflammation-
induced acute lung injury.36 High airway miR-155 levels
were found to be strongly linked to a higher production
of IFN-γ in children and decreased respiratory disease
severity.37
Besides being the receptor for the virus, ACE2 also
represents a protective factor in COVID-19. Namely, the
entry of SARS-CoV-2 into the cells through membrane
fusion markedly downregulates ACE2 receptors and
disbalance between ACE-ACE2 axes could aggravate
diabetes and cardiovascular disease and predispose to
severe COVID-19.38 Angiotensin-converting enzyme
(ACE) converts angiotensin (Ang) I to Ang II which
binds to the angiotensin II receptor 1 (AGTR1), whereas
ACE-2 converts Ang I to Ang-(1-7), which binds to
Mas receptor. Opposite to activation of ACE- Ang
II-AGTR1 axis, ACE2-Ang-(1-7)-Mas axis induces a pro-
tective mechanism of anti-inflammatory, anti-fibrotic
effects, and anti-hyperresponsiveness in respiratory
and cardiovascular system.38 In addition to angiotensin
receptor inhibitors aiming to enhance ACE2 expression,
a very recent study proposed benefits from angiotensin
receptor/MME (neprilysin) inhibitors in patients with
COVID-19, to maximize the anti-inflammatory effects and
anti-hyperresponsiveness.39
Diabetes- and periodontitis-induced increase in miR-
146a and miR-155 in oral cavity is predicted to upreg-
ulate ACE2 expression, essential SARS-CoV-2 receptors,
and modulate host antiviral response, implying possibility
of increased infectivity of these patients. Therefore, addi-
tional caution and protective measures are obligatory for
periodontists.
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